Skip to content

13F-HR filed by Athyrium Capital Management, LP

Athyrium Capital Management, LP filed this 13F-HR for the quarter ended 2022-12-31, filed 2023-02-14, with 11 holding rows worth $237,928,239.

Accession
0001567619-23-002883
Filed
2023-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2022

A holdings report, 11 entries on the cover page, a total value of $237,928,239 stated on the cover page (in dollars after the unit check, H1), rows summing to $237,928,239 with VALUE read as dollars as filed, 13F file number 028-18509. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
AMRYT PHARMA LTD - SPNR ADR03217L106COMMON EQUITY8,857,268$64,658,056dollars as filed
BIORA THERAPEUTICS INC74319FAB3NOTE 7.250%12/0103,500,000$56,262,773dollars as filedprincipal
OMEROS CORP682143AG7NOTE 5.250% 2/158,131,000$31,700,772dollars as filedprincipal
Omeros Corp682143AE2NOTE 6.250%11/121,005,000$20,240,546dollars as filedprincipal
RVL PHARMACEUTICALS PLCG6S41R101COM14,600,444$16,352,497dollars as filed
CAREMAX INC14171W103COM4,467,219$16,305,349dollars as filed
PARATEK PHARMACEUTICALS INC699374AB0Convertible Bond9,000,000$8,213,010dollars as filedprincipal
Bridgebio Pharma Inc Note 2.250 percent 2/010806XAD4Convertible20,000,000$7,753,900dollars as filedprincipal
PUMA BIOTECHNOLOGY INC74587V107COMMON STOCK1,792,114$7,580,642dollars as filed
BIORA THERAPEUTICS INC74319F107COM42,362,097$5,579,088dollars as filed
SOCIETAL CDMO INC75629F109COM2,202,420$3,281,606dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001567619-23-002883this filing2023-02-14acceptance time not in the bulk data set